Haisco Pharmaceutical Group Co., Ltd. research, develops, manufactures, and sells pharmaceuticals in China. The company offers cycloporol, dolasetron mesylate, polyene phosphatidylcholine, compound amino acid, and methylprednisolone sodium injections, as well as flupenthixol melitracen tablets. It offers its products in various therapeutic fields, including anesthesia, parenteral nutrition, tumor antiemetic, liver, gallbladder digestion, antibiotics, cardiovascular, and cerebrovascular. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2005 and is based in Shannan, China.
Metrics to compare | 002653 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship002653PeersSector | |
---|---|---|---|---|
P/E Ratio | 93.6x | 24.9x | −0.6x | |
PEG Ratio | 2.73 | −0.25 | 0.00 | |
Price/Book | 8.7x | 1.7x | 2.6x | |
Price / LTM Sales | 9.8x | 2.5x | 3.1x | |
Upside (Analyst Target) | 7.0% | 30.2% | 55.2% | |
Fair Value Upside | Unlock | 16.0% | 6.9% | Unlock |